Fineline Special Report 2025 Q1

Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

This comprehensive report examines the escalating U.S.-China trade war under the rebooted Trump administration, focusing on its unprecedented 200% tariffs targeting Chinese pharmaceutical imports. The analysis delves into the far-reaching implications for global drug supply chains, innovation ecosystems, and the stability of the $200 billion U.S. pharmaceutical market, which relies heavily on foreign imports.